Patents by Inventor Susan Bonitz

Susan Bonitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of identifying patients not suitable for high-dose cyclophosphamide treatment
    Patent number: 9279803
    Abstract: The present invention provides methods of identifying subjects that are suitable and not suitable for high-dose cyclophosphamide treatment.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: March 8, 2016
    Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Adam Kaplin, Carlos Santos
  • Cyclophosphamide in combination with anti-idiotypic vaccines
    Patent number: 8673321
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: March 18, 2014
    Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Carlos Santos
  • USE OF HIGH-DOSE, POST-TRANSPLANTATION OXAZAPHOSPHORINE DRUGS FOR REDUCTION OF TRANSPLANT REJECTION
    Publication number: 20120148577
    Abstract: A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.
    Type: Application
    Filed: October 13, 2011
    Publication date: June 14, 2012
    Applicants: ACCENTIA BIOPHARMACEUTICALS, INC., JOHNS HOPKINS UNIVERSITY
    Inventors: EPHRAIM J. FUCHS, LEO LUZNIK, ROBERT A. BRODSKY, RICHARD J. JONES, FRANCIS E. O'DONNELL, JR., CARLOS SANTOS, SUSAN BONITZ
  • Cyclophosphamide in Combination with Anti-Idiotypic Vaccines
    Publication number: 20120148611
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Application
    Filed: September 12, 2011
    Publication date: June 14, 2012
    Applicants: Accentia Biopharmaceuticals, inc., The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Carlos Santos
  • USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS
    Publication number: 20120128685
    Abstract: The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 24, 2012
    Applicants: Accentia Biopharmaceuticals, inc., The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Carlos Santos, Adam Kaplin
  • METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE CYCLOPHOSPHAMIDE TREATMENT
    Publication number: 20120129206
    Abstract: The present invention provides methods of identifying subjects that are suitable for high-dose cyclophosphamide treatment.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 24, 2012
    Applicants: Accentia Biopharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Adam Kaplin, Carlos Santos